Skip to main content
Adenovirus endocytosis and innate immune response
Projekti Hrvatske zaklade za znanost
Total cost
Start date
Jan 15th 2020
End date
Jul 14th 2024

Principal investigator

Vaccine vectors based on low seroprevalent adenovirus type 26 (HAdV26) are listed as intervention in 28 clinical trials, among which several in phase III. While HAdV26 immunogenicity in vivo is rather well described, basic biology of this virus is still insufficiently understood. Recently we reported αvβ3 integrin as a receptor required for HAdV26 successful infection of epithelial cells, however studies regarding HAdV26 endocytosis and innate immunity induced by HAdV26 infection of epithelial cells are missing. Based on our preliminary data we hypothesize that altered HAdV26 endocytosis due to binding αvβ3 integrin or modified clathrin, could lead to induction of different host innate immune response, hence influence performance of HAdV26-based vector. Therefore, the goal of AdenoIN is to investigate role of clathrin in HAdV26 transduction and address clear gap in understanding the innate immune response induced by HAdV26 infection of epithelial cells in the context of using αvβ3 integrin as a receptor and/or altered virus endocytosis. Final output of AdenoIN will be comprehensive analysis of αvβ3 integrin and clathrin mediated HAdV26 endocytosis and subsequent innate immune signaling in epithelial cells. Data and knowledge obtained within AdenoIN will be valuable for further improvement of HAdV26-based vectors.

Laboratory for Cell Biology and Signalling

This site uses cookies.. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.